Voretigene Neparvovec-Rzyl (Luxturna): Gene therapy to treat inherited vision loss

Last Updated on

December 20, 2017 –  The American Food & Drug Administration (FDA) has just approved  a novel gene therapy to treat patients with a rare form of inherited vision loss. Voretigene Neparvovec-Rzyl (Luxturna) is the first directly administered gene therapy approved to target a disease caused by mutations in a specific human gene (i.e., RPE65). Voretigene Neparvovec-Rzyl (Luxturna) is intended to treat children and adult patients with an inherited form of vision loss (i.e., inherited retinal dystrophy) resulting in blindness. 

The culmination of decades of research has resulted in three gene therapies being approved by the FDA this year for patients with serious and rare diseases and FDA believes that a turning point has been reached when it comes to this novel form of therapy.

Voretigene Neparvovec-Rzyl (Luxturna) is approved for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy that leads to vision loss and may cause complete blindness in certain patients.

Hereditary retinal dystrophies are a broad group of genetic retinal disorders that are associated with progressive visual dysfunction and are caused by mutations in any one of more than 220 different genes. Biallelic retinal pigment epithelium-specific 65 kDa protein  RPE65 gene mutation-associated retinal dystrophy affects approximately 1,000 to 2,000 patients in the U.S. Biallelic mutation carriers have a mutation (not necessarily the same mutation) in both copies of a particular gene (a paternal and a maternal mutation). The RPE65 gene provides instructions for making an enzyme (a protein that facilitates chemical reactions) that is essential for normal vision. Mutations in the RPE65 gene lead to reduced or absent levels of RPE65 activity, blocking the visual cycle and resulting in impaired vision. Individuals with biallelic RPE65 mutation-associated retinal dystrophy experience progressive deterioration of vision over time. This loss of vision, often during childhood or adolescence, ultimately progresses to complete blindness.

Voretigene Neparvovec-Rzyl (Luxturna) works by delivering a normal copy of the RPE65 gene directly to retinal cells. These retinal cells then produce the normal protein that converts light to an electrical signal in the retina to restore patient’s vision loss. Voretigene Neparvovec-Rzyl (Luxturna) uses a naturally occurring adeno-associated virus, which has been modified using recombinant DNA techniques, as a vehicle to deliver the normal human RPE65 gene to the retinal cells to restore vision.

Voretigene Neparvovec-Rzyl (Luxturna) should be given only to patients who have viable retinal cells as determined by the treating physician(s). Treatment with Voretigene Neparvovec-Rzyl (Luxturna) must be done separately in each eye on separate days, with at least six days between surgical procedures. It is administered via subretinal injection by a surgeon experienced in performing intraocular surgery. Patients should be treated with a short course of oral prednisone to limit the potential immune reaction to Voretigene Neparvovec-Rzyl (Luxturna).

The safety and efficacy of Voretigene Neparvovec-Rzyl (Luxturna) were established in a clinical development program with a total of 41 patients between the ages of 4 and 44 years. All participants had confirmed biallelic RPE65 mutations. The primary evidence of efficacy of Voretigene Neparvovec-Rzyl (Luxturna) was based on a Phase 3 study with 31 participants by measuring the change from baseline to one year in a subject’s ability to navigate an obstacle course at various light levels. The group of patients that received Voretigene Neparvovec-Rzyl (Luxturna) demonstrated significant improvements in their ability to complete the obstacle course at low light levels as compared to the control group. In the light of the fact that these have been small trials only with a very limited number of participants, the manufacturer plans to conduct a post-marketing observational study involving patients treated with Voretigene Neparvovec-Rzyl (Luxturna) in order to further evaluate its long-term clinical safety.

 

 

Tags: , , , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of
trackback

Pavani Gangireddy Images

[…]we prefer to honor many other net web-sites on the web, even when they aren’t linked to us, by linking to them. Below are some webpages worth checking out[…]

trackback

increase girth size

[…]although websites we backlink to below are considerably not related to ours, we feel they may be actually really worth a go through, so have a look[…]

trackback

waterproof wand massager

[…]Here is an excellent Weblog You may Discover Exciting that we Encourage You[…]

trackback

drywallers Vancouver

[…]usually posts some really fascinating stuff like this. If you are new to this site[…]

trackback

Double cleansing benefits

[…]just beneath, are numerous absolutely not associated sites to ours, having said that, they’re certainly really worth going over[…]

trackback

Vidalista 20mg

[…]usually posts some incredibly intriguing stuff like this. If you’re new to this site[…]

trackback

convertidor de musica

[…]below you will uncover the link to some sites that we consider you ought to visit[…]

trackback

Google

Just beneath, are a lot of completely not connected web sites to ours, nonetheless, they are certainly really worth going over.

descargar facebook
Guest

I have been exploring for a little bit for any high-quality
articles or blog posts on this sort of area . Exploring in Yahoo I finally stumbled upon this
website. Studying this information So i’m satisfied to convey that
I have an incredibly excellent uncanny feeling I found out
just what I needed. I such a lot undoubtedly will make sure to don?t put out of your mind this website and give it a glance regularly.

quest bars cheap
Guest

Have you ever thought about including a little bit more than just
your articles? I mean, what you say is important and everything.
But imagine if you added some great pictures or video clips to give your posts more, “pop”!

Your content is excellent but with pics and video clips, this blog could undeniably be one of the most beneficial in its field.
Terrific blog!

Benefits of Coconut Oil
Guest

Touche. Solid arguments. Keep up the amazing spirit.

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • New candidate cancer genes identified using math models November 15, 2019
    Computational modeling is the use of computers to simulate and study the behavior of complex systems. Computational approaches are widely adopted in the bioimedical sciences and can be used to sift through large volumes of complex data to extract recurrent patterns that may point to a disease's causes and effects.
  • Turning 'junk' DNA into gold November 15, 2019
    Mining the rich uncharted territory of the genome or genetic material of a cancer cell has yielded gold for Princess Margaret scientists: new protein targets for drug development against prostate cancer.
  • Researchers take first step toward genetic test for childhood short-sightedness November 15, 2019
    Researchers from the Universities of Cardiff and Bristol have devised a test that could in future help to identify children at risk of developing a very common eye condition.
  • Researchers link sisters' paralysis to an 'extremely rare' genetic variant November 15, 2019
    Following a nearly 25-year search across three continents, parents of a pair of sisters—who as children slowly became paralyzed from the waist down—finally have a diagnosis, according to researchers at University of Southern California (USC) and Translational Genomics Research Institute (TGen), an affiliate of City of Hope.
  • Genetic variation in individual brain cell types may predict disease risk November 15, 2019
    One might think that the primary cause of most genetically linked diseases comes from mutations in coding DNA—alterations in coding regions of the genome that can lead directly to changes in the expression of particular proteins important for a healthy body. But the majority of human DNA is non-coding DNA—regions of DNA that do not […]
  • Teens with heart disease improve exercise capacity in large clinical trial November 17, 2019
    The largest-ever clinical trial of a medication for pediatric cardiology patients found that an oral drug significantly improved exercise capacity in adolescent patients with severe, congenital single-ventricle heart defects. A study leader says the physiologic benefits represent a milestone in the care of those who have undergone the Fontan procedure, a palliative operation for single-ventricle […]
  • Rare genetic variants predispose to sudden cardiac death November 16, 2019
    By identifying rare DNA variants that substantially increase risk of sudden cardiac death, researchers have laid the foundation for efforts to identify individuals who could benefit from prevention strategies prior to experiencing symptoms.
  • Early diagnosis of pregnancy-associated heart disease linked to better outcomes November 16, 2019
    Women who are diagnosed with peripartum cardiomyopathy (PPCM) during late pregnancy or within a month following delivery are more likely to experience restored cardiac function and improved outcomes compared to those who are diagnosed later in the postpartum period, according to a new study. The findings underscore the need for increased awareness and monitoring of […]
  • Intermittent fasting increases longevity in cardiac catheterization patients November 16, 2019
    In a new study by researchers at the Intermountain Healthcare Heart Institute in Salt Lake City, researchers have found that cardiac catheterization patients who practiced regular intermittent fasting lived longer than patients who don't.
  • New catalysts remove NOx pollutants at lower temperatures November 16, 2019
    Scientists from Tokyo Metropolitan University have developed a low-temperature catalyst for removing NOx gas from industrial exhaust using ammonia. Composed of bulk 'defective' vanadium oxide instead of vanadium oxides supported on titanium oxide like in commercial catalysts, the catalyst works at lower temperatures (< 150 degrees Celsius) with much higher efficiency. The team demonstrated a […]
Top